VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies.
Scarffe, J Howard
Smith, David B
Chan, C C
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractThirty-three patients with multiple myeloma (11 untreated, 15 refractory and seven relapsed patients) have received vincristine and adriamycin infusion therapy with oral dexamethasone (VAD). The median number of course received was five. In addition 16 patients with lymphoid malignancy have received a median of four courses of VAD. Three patients who relapsed after VAD have received further VAD therapy making 52 patient treatments assessable for toxicity. Ten per cent had nausea, 4 per cent vomiting, 4 per cent total alopecia, 25 per cent constipation, 33 per cent paraesthesiae, 8 per cent proximal myopathy, 33 per cent dyspepsia, 23 per cent proven bacteraemia, and 19 per cent chest infections. Infections were not usually associated with neutropenia. Shingles was seen in four patients with myeloma, but none of the patients with lymphoid malignancy. The response rate in myeloma was 9/11, for previously untreated patients, 3/7 for relapsed, and 8/15 for refractory patients. Responses have been seen in other lymphoid malignancies-1/2 patients with relapsed acute lymphoblastic leukaemia had a complete remission. Two out of seven patients with chronic lymphocytic leukaemia achieved a partial remission, and a further three had a clinical improvement. Three out of six patients with non-Hodgkin lymphoma and one patient with macroglobulinaemia achieved a partial remission.
CitationVAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies., 5 (3):213-22 Hematol Oncol
- [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
- Authors: Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P
- Issue date: 1996 Nov-Dec
- [The efficacy of VAD chemotherapy for refractory lymphoid malignancies].
- Authors: Gotoh H, Oku N, Inaba T, Murakami S, Oku N, Takeda N, Itoh K, Fujita N, Ura Y, Nakanishi S
- Issue date: 1991 Aug
- [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
- Authors: Luo SK, Li J, Hong WD, Zhao Y, Tong XZ
- Issue date: 2005 Dec
- VAD chemotherapy as remission induction for multiple myeloma.
- Authors: Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, Fitzsimmons L, Ryder D
- Issue date: 1995 Feb
- A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma.
- Authors: Cook G, Sharp RA, Tansey P, Franklin IM
- Issue date: 1996 Jun